Literature DB >> 3873869

Immunologic evaluation in the nutritional assessment of children with cancer.

I Ramirez, J van Eys, D Carr, D Coody, P Carter-George, J Washington, E Richie, G Taylor.   

Abstract

Eighty-one newly diagnosed untreated pediatric cancer patients (48 hematopoeitic malignancies, 17 solid tumors, 16 benign diseases) were evaluated with immunologic and nutritional parameters. The mean absolute lymphocyte count was adequate in the three groups. Reduced T-lymphocytes were seen in the solid tumors. Mitogenic response of hematopoietic and solid tumor patients' lymphocytes was low. Correlation of immunologic, dietary, and nutritional factors showed that for patients with solid tumors there was a positive significant correlation between weight/height percent and lymphocyte reactivity to phytohemagglutinin, concanavalin A, and pokeweed mitogen (p less than .05). Iron intake showed a significant positive correlation with in vitro mitogen reactivity for the solid tumor group (p less than .05) and benign diseases (p less than 0.01). Immune derangements found among patients with hematopoietic malignancies can be due to replacement of normal bone marrow with malignant cells. In solid tumor patients mitogen reactivity appears to be a reflection of nutritional state, and dietary iron is a possible factor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3873869     DOI: 10.1093/ajcn/41.6.1314

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  2 in total

1.  Whole body protein metabolism in children with cancer.

Authors:  S E Daley; A D Pearson; A W Craft; J Kernahan; R A Wyllie; L Price; C Brock; C Hetherington; D Halliday; K Bartlett
Journal:  Arch Dis Child       Date:  1996-10       Impact factor: 3.791

2.  Nutritional status at diagnosis of children with malignancies in Casablanca.

Authors:  Illias Tazi; Zakia Hidane; Saadia Zafad; Mhamed Harif; Said Benchekroun; Raul Ribeiro
Journal:  Pediatr Blood Cancer       Date:  2008-10       Impact factor: 3.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.